PRCT earnings
PROCEPT BioRobotics Corporation (PRCT) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- PROCEPT BioRobotics Reports First Quarter 2026 Financial ResultsSAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026. "Over the past six months, we have taken decisive actions to reset the organization by sharpening our focus on operational excellence, accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing.
- PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2026 after market close on Wednesday, April 29, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/rdtftqik/ Dial-in registration for sell-side research
- PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue GuidanceSAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. "In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter," said Larry Wood, Chief Executive Officer. "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commer
- PROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor DaySAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that it has updated the timing of its previously announced fourth quarter 2025 earnings conference call and Investor Day due to significant travel disruptions caused by inclement weather. The Company will report financial results for the fourth quarter of 2025 after market close on Wednesday, February 25, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it has r
- PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York CitySAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it will host an in-person investor day event on Wednesday, February 25, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time. Guests are encouraged to register in advance by clic
- PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue GuidanceSAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2025. Recent Highlights Total revenue of $83.3 million for the third quarter of 2025, an increase of 43% compared to the prior year period in 2024U.S. handpiece and consumables revenue of $44.4 million for the third quarter of 2025, an increase of 50% compared to the prior year period in 2024The installed base in the U.S. increased by 58 robotic systems in the third quarter of 2025U.S
- PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/ojteo5eq/ Dial-in registration for sell-side research
- PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue GuidanceSAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2025. Recent Highlights Total revenue of $79.2 million for the second quarter of 2025, an increase of 48% compared to the prior year period in 2024U.S. handpiece and consumables revenue of $43.1 million for the second quarter of 2025, an increase of 58% compared to the prior year period in 2024Sold 51 robotic systems in the U.S. in the second quarter of 2025U.S. system and rental revenue o
- PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025SAN JOSE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2025 after market close on Wednesday, August 6, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/apg8aowj Dial-in registration for sell-side research a
- PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue GuidanceSAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the prior year period in 2024U.S. handpiece and consumables revenue of 38.0 million for the first quarter of 2025, an increase of 61% compared to the prior year period in 2024Sold 43 new robotic sy
- PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, NevadaSAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Members of PROCEPT BioRobotics' management team presenting include: Reza Zadno – Chief Executive OfficerKevin Waters – Chief Financial OfficerSham Shiblaq – Chief Commercial OfficerBarry Templin – Chief Technology Officer Clinical perspectives will also be
- PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 ResultsSAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue of approximately $68.2 million for the fourth quarter of 2024, an increase of 57% compared to the prior year periodU.S. system revenue of $27.6 million for the fourth quarter of 2024, an increase of 67% compared to the prior year periodSold 60 new robotic systems in the U.S. in the fourth quarter of 2024 at a blended average selling price of a
- PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare ConferenceSAN JOSE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2024 after market close on Tuesday, February 25, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/q33jvv92 Dial-in registration for sell-side research analysts
- PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA GuidanceSAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $58.4 million for the third quarter of 2024, an increase of 66% compared to the prior period in 2023U.S. handpiece and consumables revenue of $29.6 million for the third quarter of 2024, an increase of 74% compared to the prior period in 2023Sold 45 robotic systems in the U.S. in the third quarter of 2024
- PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/yhamkcsz Dial-in registration for sell-side re
- PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® TherapySAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes. "We are pleased to bring the H
- PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA GuidanceSAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the prior period in 2023U.S. handpiece and consumables revenue of $27.3 million for the second quarter of 2024, an increase of 101% compared to the prior period in 2023Sold 47 robotic systems in the U.S. in the second quarter of 2024U.S. system and rental revenue of $17.
- PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/qsztnzfu/ Dial-in registration for sell-side research
- PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceSAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024. Recent Highlights Total revenue of $44.5 million for the first quarter of 2024, an increase of 83% compared to the prior year period in 2023U.S. handpiece and consumables revenue of $23.6 million for the first quarter of 2024, an increase of 101% compared to the prior year period in 2023Sold 38 U.S. robotic systems in the first quarter of 2024U.S. system and rental revenue of
- PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 1, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/2ag2438d Dial-in registration for sell-side research an
- PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 ResultsSAN JOSE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2023. Recent Highlights Total revenue of approximately $43.6 million for the fourth quarter of 2023, an increase of 83% compared to the prior year periodU.S. system and rental revenue of $16.6 million for the fourth quarter of 2023, an increase of 59% compared to the prior year periodU.S. handpiece and consumables revenue of $21.6 million for the fourth quarter of 2023, an increase of 109% compared
- PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 millionSAN JOSE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2023. Preliminary, Unaudited Revenue Highlights: Total revenue for the fourth quarter of 2023 is expected to be in the range of $43.3 million to $43.6 million, compared to $23.8 million in the prior year period. Total U.S. revenue of approximately $40.0 million to $40.3 million for the fourth quarter of 2023Total U.S. Handpieces sold of approximately 6,400 resultin
- PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue GuidanceSAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2023. Recent Highlights Total revenue of $35.1 million for the third quarter of 2023, an increase of 72% compared to the same period in 2022U.S. handpiece and consumables revenue of $17.0 million for the third quarter of 2023, an increase of 113% compared to the same period in 2022Third quarter of 2023 U.S. monthly account utilization increased sequentially by 5% compared to the se
- PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2023 after market close on Wednesday, November 1, 2023. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/cycnvr77 Dial-in registration for s
- PROCEPT BioRobotics® Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue GuidanceREDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2023. Recent Highlights Total revenue of $33.1 million for the second quarter of 2023, an increase of 98% compared to the same period in 2022Sold a record 40 U.S. robotic systems in the second quarter of 2023U.S. system and rental revenue of $14.8 million for the second quarter of 2023, an increase of 74% compared to the same period in 2022U.S. handpiece and consumables revenue of $
- PROCEPT BioRobotics to Report Second Quarter 2023 Financial Results on July 27, 2023REDWOOD CITY, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2023 before market open on Thursday, July 27, 2023. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/fw7aiho7 Dial-in registration for sell-sid
- PROCEPT BioRobotics Reports First Quarter 2023 Financial Results and Increases 2023 Revenue GuidanceREDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2023. Recent Highlights Total revenue of $24.4 million for the first quarter of 2023, an increase of 72% compared to the prior year period in 2022U.S. handpiece and consumables revenue of $11.8 million for the first quarter of 2023, an increase of 165% compared to the prior year period in 2022U.S. system and rental revenue of $8.8 million for the first
- PROCEPT BioRobotics to Report First Quarter 2023 Financial Results on April 27, 2023 and Present at the Bank of America 2023 Health Care Conference in Las VegasREDWOOD CITY, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2023 before market open on Thursday, April 27, 2023. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/qk7hrxz5 Dial-in registration for sell-side researc
- PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2022 ResultsREDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2022. Recent Highlights Total revenue of $75.0 million for full year 2022, an increase of 118% compared to 2021Total revenue of $23.8 million for the fourth quarter of 2022, an increase of 135% compared to the prior year periodU.S. system and rental revenue of $10.4 million for the fourth quarter of 2022, an increase of 109% compared to the prior year periodU.S. handpiece and consumables revenu
- PROCEPT BioRobotics Announces Preliminary Fourth Quarter and Fiscal Year 2022 RevenueREDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2022. Preliminary, Unaudited Revenue Highlights: Total revenue for the fourth quarter of 2022 is expected to be in the range of $23.6 million to $23.8 million, compared to $10.1 million in the prior year period Total U.S. revenue of $21.6 million to $21.8 million for the fourth quarter of 2022U.S. system sales of 28 robots, resulting in total U.S. system reven
- PROCEPT BioRobotics Reports Third Quarter 2022 Financial Results and Increases 2022 Revenue GuidanceREDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2022. Recent Highlights Total Revenue of $20.3 million for the third quarter of 2022, an increase of 135% compared to the prior year periodU.S. system and rental revenue of $9.8 million for the third quarter of 2022, an increase of 95% compared to the prior year periodU.S. handpiece and consumables revenue of $8.0 million for the third quarter of 2022, an increase of 267% compared
- PROCEPT BioRobotics to Report Third Quarter 2022 Financial Results on November 3, 2022REDWOOD CITY, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2022 after market close on Thursday, November 3, 2022. The Company's management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/ivt2yxvx Dial-in registra
- PROCEPT BioRobotics Reports Second Quarter 2022 Financial Results and Increases 2022 Revenue GuidanceREDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2022. Recent Highlights Total Revenue of $16.7 million for the second quarter of 2022, an increase of 97% compared to the prior year periodU.S. system and rental revenue of $8.5 million for the second quarter of 2022, an increase of 79% compared to the prior year periodU.S. handpiece and consumables revenue of $5.7 million for the second quarter of 2022, an increase of 246% compared t
- PROCEPT BioRobotics to Report Second Quarter 2022 Financial Results on August 4, 2022REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. The company's management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/87bcav5x [edge.media-server.com] Dial-in regi
- PROCEPT BioRobotics Reports First Quarter 2022 Financial Results and Increases 2022 Revenue GuidanceREDWOOD CITY, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2022. Recent Highlights Total Revenue of $14.2 million for the first quarter of 2022, an increase of 97% compared to the prior year period in 2021U.S. system and rental revenue of $7.8 million for the first quarter of 2022, an increase of 70% compared to the prior year period in 2021U.S. handpiece and consumables revenue of $4.4 million for the first quarter of 2022, an increa
- PROCEPT BioRobotics Corp. to Report First Quarter 2022 Financial Results on May 5, 2022 and attend the 2022 Bank of America Healthcare Conference on May 11, 2022REDWOOD CITY, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (866)-374-5140 for domestic callers or (808)-238-9813 for international callers, using conference ID: 25960799. Live audio of the webcast will be av
- PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2021 Financial ResultsREDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights Revenue of $10.1 million for the fourth quarter of 2021 and $34.5 million for the full year of 2021, compared to $3.2 million and $7.7 million, respectively, from the same periods of 2020U.S. system and rental revenue of $5.0 million for the fourth quarter of 2021, compared to $1.2 million in the prior year periodU.S. handpiece and consumables revenue of $3
- PROCEPT BioRobotics Corp. to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report finical results for the fourth quarter and full year 2021 before market open on Tuesday, March 8, 2022. The company's management will webcast a corresponding conference call beginning at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (800) 306-0005 for domestic callers or (209) 905-5968 for international callers, using conference ID: 2515587. Live audio of the webc
- PROCEPT BioRobotics Corp. to Report Third Quarter 2021 Financial Results on November 4, 2021REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter 2021 after the market close on Thursday, November 4, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (800) 306-0005 for domestic callers or (209) 950-5968 for international callers, using conference ID: 7198987. Live audio of the webcast wil